Combining the Target Trial and Estimand Frameworks to Define the Causal Estimand: An Application Using Real-World Data to Contextualize a Single-Arm Trial

被引:5
|
作者
Hampson, Lisa V. [1 ,4 ]
Chu, Jufen [2 ]
Zia, Aiesha [1 ]
Zhang, Jie [2 ]
Hsu, Wei-Chun [3 ]
Parzynski, Craig S. [3 ]
Hao, Yanni [2 ]
Degtyarev, Evgeny [1 ]
机构
[1] Novartis Pharm AG, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Genesis Res, Hoboken, NJ USA
[4] Novartis Pharm AG, Postfach 4002, Basel, Switzerland
来源
STATISTICS IN BIOPHARMACEUTICAL RESEARCH | 2024年 / 16卷 / 01期
关键词
Causal inference; Estimand; External control arm; Real-world evidence; Target trial framework; LYMPHOMA;
D O I
10.1080/19466315.2023.2190931
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Single-arm trials (SATs) may be used to support regulatory submissions in settings where there is a high unmet medical need and highly promising early efficacy data undermine the equipoise needed for randomization. In this context, patient-level real-world data (RWD) may be used to create an external control arm (ECA) to contextualize the SAT results. However, naive comparisons of the SAT with its ECA will yield biased estimates of causal effects if groups are imbalanced with regards to (un)measured prognostic factors. Several methods are available to adjust for measured confounding, but the interpretation of such analyses is challenging unless the causal question of interest is clearly defined, and the estimator is aligned with the estimand. Additional complications arise when patients in the ECA meet the inclusion/exclusion criteria for the SAT at multiple timepoints. In this article, we use a case-study of a pivotal SAT to illustrate how a combination of the target trial and the ICH E9(R1) estimand frameworks can be used to define the target estimand and avoid common methodological pitfalls. We also propose an approach to address the challenge of how to define an appropriate time zero for external controls who meet the SAT inclusion/exclusion criteria at several timepoints.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [21] Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial
    Serrano, Philippe
    Yuen, Hiu Wah
    Akdemir, Julia
    Hartmann, Markus
    Reinholz, Tatjana
    Peltier, Sylvie
    Ligensa, Tanja
    Seiller, Claudia
    Bourhis, Achta Paraiso Le
    DRUG DISCOVERY TODAY, 2022, 27 (06) : 1706 - 1715
  • [22] Bihormonal fully closed-loop system for the treatment of type 1 diabetes: a real-world multicentre, prospective, single-arm trial in the Netherlands
    van Bon, A. C.
    Blauw, H.
    Jansen, T. J. P.
    Laverman, G. D.
    Urgert, T.
    Geessink-Mennink, J.
    Mulder, A. H.
    Out, M.
    Veldman, R. Groote
    Onvlee, A. J.
    Schouwenberg, B. J. J. W.
    Vermeulen, M. A. R.
    Diekman, M. J. M.
    Gerding, M. N.
    van Wijk, J. P. H.
    Klaassen, M.
    Witkop, M.
    De Vries, J. H.
    LANCET DIGITAL HEALTH, 2024, 6 (04): : e272 - e280
  • [23] Using real-world external controls to support drug approval: An interactive framework using oncology trial and real-world data
    Hester, Laura L.
    Rivera, Donna R.
    Lund, Jennifer L.
    Golozar, Asieh
    Davis, Kourtney
    Seeger, John D.
    Sansbury, Leah
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 4 - 5
  • [24] Economic Evaluation of Cancer Drugs using Clinical Trial and Real-World Data
    Shanmugam, Ramalingam
    JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION, 2021, 91 (09) : 1908 - 1909
  • [25] Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial Authors' reply
    Xie, Yan
    Al-Aly, Ziyad
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (12): : 895 - 896
  • [26] Regulatory-grade clinical trial design using real-world data
    Levenson, Mark S.
    CLINICAL TRIALS, 2020, 17 (04) : 377 - 382
  • [27] COMPARATIVE EFFECTIVENESS USING EXTERNAL CONTROLS FOR SINGLE-ARM TRIALS OF PEMBROLIZUMAB IN TUMOR-AGNOSTIC INDICATIONS LEVERAGING REAL-WORLD DATA
    Chen, Y.
    Martin, P.
    Ye, S.
    Inoue, L.
    Basu, A.
    Carlson, J. J.
    VALUE IN HEALTH, 2023, 26 (06) : S363 - S364
  • [28] Creation of a real-world cohort of hyperkalemia patients using Danish health care data to simulate the control population of a single arm clinical intervention trial
    Thomsen, Reimar W.
    Christensen, Lotte B.
    Nicolaisen, Sia K.
    Kun, Kim
    Hasvold, Pal
    Palaka, Eirini
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 408 - 409
  • [29] APPLICATION OF A NOVEL BAYESIAN DYNAMIC BORROWING APPROACH USING ANONYMIZED FINNISH REAL-WORLD DATA AS AN EXTERNAL CONTROL ARM TO AUGMENT AN INTERNAL CONTROL ARM OF A RANDOMIZED CLINICAL TRIAL
    Potts, J.
    Wang, M. D.
    VALUE IN HEALTH, 2024, 27 (06) : S264 - S264
  • [30] COMBINING CLINICAL TRIAL AND REAL-WORLD EVIDENCE DATA IN THE ASSESSMENT OF PUBLIC HEALTH IMPACT IN HTA EVALUATIONS
    Leleu, H.
    Nucit, A.
    Lefevre, C.
    Salvignol, O.
    Grenier, B.
    Coulibaly, C.
    Jolivel, R.
    Blachier, M.
    VALUE IN HEALTH, 2022, 25 (01) : S198 - S198